A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 623-636

  Trigka, Eleni Andriana ^a   Levidou, Georgia ^a   Saetta, Angelica A ^a   Chatziandreou, Ilenia ^a   Tomos, Periklis ^a   Thalassinos, Nikolaos ^b   Anastasiou, Nikolaos ^b   Spartalis, Eleftherios ^a   Kavantzas, Nikolaos ^a   Patsouris, Efstratios ^a   Korkolopoulou, Penelope ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b 1st IKA Hospital   (Greece)

Author keywords

AKT1; Immunohistochemistry; K RAS; Non small cell lung cancer; PI3K AKT mTOR pathway; PIK3CA; PTEN

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; S6 KINASE;

ADULT; AGED; AKT1 GENE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL FEATURE; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ENZYME SUBUNIT; EXON; FEMALE; GENE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PTEN GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84879636044     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2512     Document Type: Article

References (52)

1. Travis WD; IASLC Staging Committee: Reporting lung cancer pathology specimens. Impact of the anticipated 7th edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 54: 3-11, 2009.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics: 2007. CA Cancer J Clin 57: 43-66, 2007.
3. Vivanco I and Sawyers CL: The phosphatidyloinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
4. Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603, 2005. (Pubitemid 41540408)
5. Sarbassov DD, Ali SM, Kim DH, et al: Rictor, a novel binding pattern of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302, 2004. (Pubitemid 38991819)
6. Hay N and Sonenberg N: Upstream and downstream of mTOR Genes Dev 18: 1926-1945, 2004. (Pubitemid 39071573)
7. Gingras AC, Gypi SP, Raught B, et al: Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13: 1422-1437, 1999. (Pubitemid 29270247)
8. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004. (Pubitemid 38579480)
9. Yu J, Zhang Y, McIlroy J, et al: Regulation of the p85/p110 phosphstidyloinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18: 1379-1387, 1998. (Pubitemid 28100902)
10. Miled N, Yan Y, Hon WC, et al: Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317: 239-242, 2007. (Pubitemid 47076198)
11. Yamamoto H, Hisayuki S, Masaharu N, et al: PI3KCA mutations and copy number gains in human lung cancer. Cancer Res 68: 693-621, 2008.
12. Scrima M, De Marco C, Fabiani F, et al: Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatidyl-inositol-3 kinase. PLoS One 7: e30427, 2012.
13. Marti A and Felip E: PI3K pathway in NSCLC. Front Oncol 1: 55, 2012.
14. Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998. (Pubitemid 28458022)
15. Wangpaichitr M, Wu C, You M, et al: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591: 124-127, 2008.
16. Balsara BR, Pei J,Mitsuuchi Y, et al: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004. (Pubitemid 39534841)
17. Okudela K, Suzuki M, Kageyama S, et al: PIK3CA mutation and amplification in human lung cancer. Pathol Int 57: 664-671, 2007. (Pubitemid 47353042)
18. Yoshizawa A, Fukuoka J, Shimizu S, et al: Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16: 240-248, 2010.
19. Anagnostou VK, Bepler G, Syrigos KN, et al: High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 15: 4157-4164, 2009.
20. Tang JM, He QY, Guo RX, et al: Phosphorylated AKT overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
21. Liu D, Huang Y, Chen B, et al: Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer 117: 3763-3673, 2011.
22. Dobashi Y, Suzuki S, Matsubara H, et al: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 115: 107-118, 2009.
23. McDonald JM, Pelloski CE, Ledoux A, et al: Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res 14: 7832-7837, 2008.
24. Khoury T, Alrawi S, Ramnath N, et al: Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 10: 58-66, 2009.
25. Wang R, Genng J, Wang JH, et al: Overexpression of eukaryotic initiation factor 4E (eIF4E) ad its clinical significance in lung adenocarcinoma. Lung Cancer 66: 237-244, 2009.
26. Oh MH, Lee HJ, Yoo SB, et al: Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch 460: 601-609, 2012.
27. Zito CR, Jilaveanu LB, Anagnostou V, et al: Multi-level targeting of the phosphatidyloinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 7: e31331, 2012.
28. Gately K, Al-Alao B, Dhillon T, et al: Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer 75: 217-222, 2012.
29. Dhillon T, Mauri FA, Belezza G, et al: Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 5: 314-319, 2010.
30. Lim WT, Zhang WH, Miller CR, et al: PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 17: 853-857, 2007.
31. Shi Y, Chen L, Li J, et al: Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol 32: 381-389, 2011.
32. David O, Jett J, LeBeau H, et al: Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865-6871, 2004. (Pubitemid 39383035)
33. Korkolopoulou P, Levidou G, Trigka EA, et al: A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int: E1237-E1248, 2012.
34. Levidou G, Saetta AA, Gigelou F, et al: ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. World J Surg Oncol 10: 47, 2012.
35. Rojo F, Najera L, Lirola J, et al: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13: 81-89, 2007. (Pubitemid 46121856)
36. Fujisaka Y, Yamada Y, Yamamoto N, et al: A phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40: 732-738, 2010.
37. Pal SK, Figlin RA and Reckamp KL: The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer 9: 340-345, 2008.
38. An SJ, Chen ZH, Su J, et al: Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 7: e40109, 2012.
39. Thomas G: The S6 kinase signaling pathway in the control of development and growth. Biol Res 35: 305-313, 2002.
40. Riemenschneider MJ, Betensky RA, Pasedag SM, et al: AKT activation in human glioblastomas enhances proliferation via TSC1 and S6 kinase signaling. Cancer Res 66: 5618-5623, 2006. (Pubitemid 43927113)
41. Han S, Khuri FR and Roman J: Fibronectin stimulates non-small cell lung cancinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66: 315-323, 2006. (Pubitemid 43166038)
42. Johnson SM, Gulhati P, Rampy BA, et al: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210: 767-778, 2010.
43. Bose S, Chandran S, Mirocha JM and Bose N: The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19: 238-245, 2009. (Pubitemid 43117608)
44. Pantuck AJ, Seligson DB, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109: 2257-2267, 2007. (Pubitemid 46801555)
45. Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054-1063, 2011.
46. Liliental J, Moon SY, Lesche R, et al: Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol 10: 401-404, 2000. (Pubitemid 30213387)
47. Dai B, Kong YY, Ye DW, et al: Activation of the mammalian target of rapamycin signaling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 104: 1009-1016, 2009.
48. Seki N, Takasu T, Mandai K, et al: Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clic Cancer Res 8: 3046-3053, 2002.
49. Rosenwald IB, Hutzler MJ, Wang S, et al : Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioalveolar but not in squamous cell carcinomas of the lung. Cancer 92: 2164-2171, 2001.
50. Sun SY, Rosenberg LM, Wang X, et al: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058, 2005. (Pubitemid 41161231)
51. Armengol G, Rojo F, Castellvi J, et al: 4E-binding protein 1: a key molecular 'funnel factor' in human cancer with clinical implications. Cancer Res 67: 7551-7555, 2007. (Pubitemid 47281345)
52. Dumstorf CA, Konicek BW, McNulty AM, et al: Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptopis. Mol Cancer Ther 9: 3158-3163, 2010.